Omburtamab
Omburtamab is a humanized monoclonal antibody targeting B7-H3 (CD276) . Omburtamab selectively binds to B7-H3 highly expressed on the surface of tumor cells and activates anti-tumor immune responses mediated by T cells and natural killer (NK) cells. Omburtamab can promote the specific infiltration of CAR-T cells into tumors, enhance the killing function of NK cells through the CD16 signaling pathway, and regulate tumor cell glucose metabolism (such as inhibiting the Warburg effect) . Omburtamab has the potential to inhibit solid tumors such as non-small cell lung cancer (NSCLC) [1][2].
Product Specifications
CAS Number
1895083-75-6
UNSPSC
12352203
Target
CD276/B7-H3
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/omburtamab.html
Purity
99.16
Solubility
10 mM in DMSO
Smiles
[Omburtamab]
Molecular Weight
(144.98 kDa)
References & Citations
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Tyrosinase-Related Protein-1 (TYRP-1) (Melanoma Marker) (TYRP1/3280), CF640R conjugate, 0.1mg/mL
![2-Chloro-N-(4'-chloro-5-hydroxy [1,1'-biphenyl]-2-yl)-3-pyridinecaboxamide-D4](https://cdn.genprice.uk/products/572/3309088540938/imageurl/trc-c587856-1mg.webp)
2-Chloro-N-(4'-chloro-5-hydroxy [1,1'-biphenyl]-2-yl)-3-pyridinecaboxamide-D4
CD45 / LCA (B-Cell Marker) (PTPRC/1975R), CF488A conjugate, 0.1mg/mL
ARF1 (Golgi Apparatus Marker) (ARF1/2117), CF740 conjugate, 0.1mg/mL
